Who’s Hired? Endo Names New CEO
While Mylan and Pfizer’s Viatris Builds Its Leadership Team
Endo has named a new CEO and CFO, while Mylan and Pfizer’s Viatris has found its CFO and announced its full roster of board members. Meanwhile, Assogenerici names the leaders of its value added medicines sector group, law firm Fish & Richardson gets a new CEO and France appoints a new health minister.
You may also be interested in...
Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.
Industry veteran Paul Bisaro has joined the board of TherapeuticsMD and Mylan has announced new Viatris appointments, while Amneal brings in a new CFO at the same time as Fresenius Kabi’s biosimilars head exits the company.